Insider · CIK 0001739363
Hisham Shiblaq
Files at PRCT (PROCEPT BioRobotics Corp). First filing Mar 7, 2024, latest Jun 6, 2025.
In brief
Hisham Shiblaq files SEC Form 4 as officer at PRCT (PROCEPT BioRobotics Corp). Since Mar 7, 2024, Hisham Shiblaq has reported 0 open-market buys worth $0 and 3 open-market sells worth $1.4M, the latest filed on Jun 6, 2025.
A track record needs three past buys with six months of prices behind them; Hisham Shiblaq has 0, so none is measured yet.
The newest scored trade: sold $1.3M of PRCT on Jun 6, 2025, filed Jun 6, 2025, scored 38 (weak).
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
PRCT: PROCEPT BioRobotics Corp
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 38Weak | PROCEPT BioRobotics Corp | $1.3M 20,000 shares | -24% | +29% from low-37% from high | |
| 30Weak | PROCEPT BioRobotics Corp | $12k 244 shares | -0% | +96% from low-4% from high | |
| 39Weak | PROCEPT BioRobotics Corp | $82k 1,759 shares | -3% | +90% from low-7% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jun 6, 2025 | PRCT PROCEPT BIOROBOTICS CORPORATION | 20,000 0.04% of outstanding | $1.3M | Jun 6, 2025 | none |
| Mar 18, 2025 | PRCT PROCEPT BioRobotics Corp | 247 0.00% of outstanding | $14k | Mar 18, 2025 | $220k |
| Mar 6, 2025 | PRCT PROCEPT BioRobotics Corp | 3,588 0.01% of outstanding | $220k | Mar 6, 2025 | none |
Transactions
Every row this insider has filed, 9 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 6, 2025 | PRCT PROCEPT BioRobotics Corp | MOption exercise Common Stock | +20,000 | $5.18 | $104k | 83,133 | Jun 6, 2025 |
| Jun 6, 2025 | PRCT PROCEPT BioRobotics Corp | SOpen-market sale Common Stock | -12,296 | $63.71 | $783k | 70,837 | Jun 6, 2025 |
| Jun 6, 2025 | PRCT PROCEPT BioRobotics Corp | SOpen-market sale Common Stock | -5,904 | $64.64 | $382k | 64,933 | Jun 6, 2025 |
| Jun 6, 2025 | PRCT PROCEPT BioRobotics Corp | SOpen-market sale Common Stock | -1,800 | $65.35 | $118k | 63,133 | Jun 6, 2025 |
| Jun 6, 2025 | PRCT PROCEPT BioRobotics Corp | MOption exercise Stock Option (Right to Buy)derivative | -20,000 | $0.00 | $0 | 11,578 | Jun 6, 2025 |
| Mar 18, 2024 | PRCT PROCEPT BioRobotics Corp | SOpen-market sale Common Stock | -244 | $48.83 | $12k | 55,860 | Mar 20, 2024 |
| Mar 6, 2024 | PRCT PROCEPT BioRobotics Corp | AGrant or award Common Stock | +26,449 | $0.00 | $0 | 57,863 | Mar 7, 2024 |
| Mar 6, 2024 | PRCT PROCEPT BioRobotics Corp | SOpen-market sale Common Stock | -1,759 | $46.67 | $82k | 56,104 | Mar 7, 2024 |
| Mar 6, 2024 | PRCT PROCEPT BioRobotics Corp | AGrant or award Stock Option (Right to Buy)derivative | +23,038 | $0.00 | $0 | 23,038 | Mar 7, 2024 |
Questions about Hisham Shiblaq
Answered from the filings on this page, as of the latest one.
Is Hisham Shiblaq buying or selling?
Not in the last 12 months. Hisham Shiblaq's latest open-market trade on SEC Form 4 was sold $1.3M of PRCT on Jun 6, 2025.
How did Hisham Shiblaq's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Hisham Shiblaq has 0.
Where does Hisham Shiblaq file Form 4?
Hisham Shiblaq has filed Form 4 at PRCT (PROCEPT BioRobotics Corp) as EVP, Chief Comm. Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.